Samsung Biologics joins the Frontier 1.5D project as part of the 2050 Carbon Neutral Initiative

0

INCHEON, South Korea, September 13, 2021 / PRNewswire / – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization, today announced the signing of a Memorandum of Understanding to participate in the Frontier 1.5D initiative aiming to develop a climate risk management model within the framework of 2050. Carbon neutral strategy in response to the current challenges associated with global climate change.


Samsung Biologics joins the Frontier 1.5D project as part of the 2050 Carbon Neutral Initiative

The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5 ° C above pre-industrial levels, and local business leaders have joined forces with the British Embassy, Ewha Women’s University, Financial Supervisory Service, to collectively thrive for a net zero future. Frontier 1.5D should address the uncertainties associated with climate change by analyzing the financial impact of climate change and climate response policies such as GHG reductions.

Samsung Biologics, as the representative of the commercial sector, will closely monitor, identify and provide data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) with Science Based Targets (SBT) to determine the risks and opportunities for climate change. as well as the financial impact to translate this data into action.

“We are proud and honored to be part of the vital Frontier 1.5D initiative to ultimately redefine energy efficiency and reusable energy through reduced GHG emissions,” said John rim, CEO of Samsung Biologics. “In addition to our primary mission to provide a healthier and more sustainable future for humanity, Samsung Biologics will support the development of medium and long-term climate change strategies and action plans as part of our efforts to decarbonization to achieve a net zero future. “

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering advanced contract development, manufacturing and laboratory testing services. With proven regulatory approvals, the largest capacity and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacture of biologics every step of the way while meeting evolving needs. biopharmaceuticals. companies around the world. For more information visit samsungbiologics.com.

Samsung Biologics contact:

Senior Director of Global Public Relations
Claire Kim
cair.kim@samsung.com

Related links:

https://samsungbiologics.com/en


Source link

Share.

Leave A Reply